<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03530514</url>
  </required_header>
  <id_info>
    <org_study_id>R4461-HV-1794</org_study_id>
    <secondary_id>2018-000327-14</secondary_id>
    <nct_id>NCT03530514</nct_id>
  </id_info>
  <brief_title>A Study to Examine the Safety, Tolerability and Biological Effects of REGN4461 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1 Randomized, Double-Blind, Placebo-Controlled, 2-Part Study to Assess the Safety and Tolerability, Pharmacokinetics, And Pharmacodynamics of Single and Multiple Doses of REGN4461 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the safety and tolerability of REGN4461 in
      healthy subjects. The secondary objectives of the study are to:

        -  Characterize the Pharmacokinetic (PK) profile of single and repeated doses of REGN4461

        -  Estimate the effects of repeated doses of REGN4461 on body weight

        -  Assess the effects of repeated doses of REGN4461 on ad lib energy intake in overweight
           and obese subjects

        -  Evaluate the effects of single and repeated doses of REGN4461 on soluble forms of
           lipid-regulating proteins levels over time

        -  Assess the immunogenicity of single and repeated doses of REGN4461
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 2-part study of the safety, tolerability, PK and pharmacodynamic (PD) of single and
      repeated doses of REGN4461 in healthy participants. In Part A, healthy lean or overweight
      subjects will be enrolled to evaluate the safety, tolerability, PK, and PD of single
      ascending intravenous (IV) and subcutaneous (SC) doses. Interim PK and safety information
      from Part A will be used to select the dose level, frequency, and mode of administration (IV
      or SC) for repeat dosing in Part B.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 14, 2018</start_date>
  <completion_date type="Anticipated">October 6, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 21, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Week 12 (End of treatment period)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentrations of REGN4461 in serum over time</measure>
    <time_frame>Up to week 27 (End of study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in body weight in overweight or obese subjects</measure>
    <time_frame>Baseline to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in body weight in overweight or obese subjects</measure>
    <time_frame>Baseline to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in caloric intake in response to standardized meals in overweight or obese subjects</measure>
    <time_frame>Baseline to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipid-regulating protein levels over time after single doses of REGN4461</measure>
    <time_frame>Up to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipid-regulating protein levels over time after repeated doses of REGN4461</measure>
    <time_frame>Up to week 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies to REGN4461 over time after single doses of REGN4461</measure>
    <time_frame>Up to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies to REGN4461 over time after repeated doses of REGN4461</measure>
    <time_frame>Up to week 27</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">169</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Part A: Single dose cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1 will receive a single IV dose of REGN4461 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Single dose cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2 will receive a sequential ascending single IV dose of REGN4461 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Single dose cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3 will receive a sequential ascending single IV dose of REGN4461 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Single dose cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 4 will receive a sequential ascending single SC dose of REGN4461 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Single dose cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 5 will receive a sequential ascending single IV dose of REGN4461 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Single dose cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 6 will receive a sequential ascending single SC dose of REGN4461 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Single dose cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 7 will receive a sequential ascending single IV dose of REGN4461 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Single dose cohort 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 8 will receive a single IV dose of REGN4461 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Single dose cohort 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 9 will receive a single IV dose of REGN4461 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Repeated dose cohort 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 10 will receive repeated IV or SC doses of REGN4461 or matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN4461</intervention_name>
    <description>REGN4461</description>
    <arm_group_label>Part A: Single dose cohort 1</arm_group_label>
    <arm_group_label>Part A: Single dose cohort 2</arm_group_label>
    <arm_group_label>Part A: Single dose cohort 3</arm_group_label>
    <arm_group_label>Part A: Single dose cohort 4</arm_group_label>
    <arm_group_label>Part A: Single dose cohort 5</arm_group_label>
    <arm_group_label>Part A: Single dose cohort 6</arm_group_label>
    <arm_group_label>Part A: Single dose cohort 7</arm_group_label>
    <arm_group_label>Part A: Single dose cohort 8</arm_group_label>
    <arm_group_label>Part A: Single dose cohort 9</arm_group_label>
    <arm_group_label>Part B: Repeated dose cohort 10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo-matching REGN4461</description>
    <arm_group_label>Part A: Single dose cohort 1</arm_group_label>
    <arm_group_label>Part A: Single dose cohort 2</arm_group_label>
    <arm_group_label>Part A: Single dose cohort 3</arm_group_label>
    <arm_group_label>Part A: Single dose cohort 4</arm_group_label>
    <arm_group_label>Part A: Single dose cohort 5</arm_group_label>
    <arm_group_label>Part A: Single dose cohort 6</arm_group_label>
    <arm_group_label>Part A: Single dose cohort 7</arm_group_label>
    <arm_group_label>Part A: Single dose cohort 8</arm_group_label>
    <arm_group_label>Part A: Single dose cohort 9</arm_group_label>
    <arm_group_label>Part B: Repeated dose cohort 10</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria

        Part A:

          1. Males and females 18 to 50 years of age, inclusive

          2. Body mass index (BMI) from 18.5 to &lt;30.0 kg/m^2

          3. Participant is judged by the investigator to be in good health and free from major
             comorbidities based on medical history, physical examination, laboratory safety tests
             performed at screening and/or prior to administration of initial dose of study drug

        Part B:

          1. Males and females 18 to 65 years of age, inclusive

          2. Have a body mass index (BMI) from 25.0 to 40.0 kg/m^2

          3. Participant is judged by the investigator to be free from major comorbidities based
             upon medical history, physical examination, laboratory safety tests performed at
             screening and/or prior to administration of initial dose of study drug. Subjects can
             have a history of mild hyperlipidemia and/or mild hypertension but should be on stable
             doses of lipid lowering or blood pressure lowering medicines for at least 2 months
             prior to screening

        Key Exclusion Criteria

        Part A:

          1. History of type 1 or 2 diabetes or prediabetes or with fasting blood glucose (FBG) at
             screening ≥ 100mg/dL or with HbA1c at screening of ≥ 5.7%.

          2. Fasting LDL-C ≥ 130mg/dL, TG ≥ 250 mg/dL

        Part B:

          1. History of type 1 or 2 diabetes or with FBG at screening ≥ 126 mg/dL or with HbA1c at
             screening of ≥ 6.5%. A diagnosis of &quot;pre-diabetes&quot; is allowed.

          2. Fasting LDL-C ≥ 160 or TG ≥ 500 mg/dL

        Key Exclusion Criteria (Parts A and B):

          1. Hospitalization (ie, &gt;24 hours) for any reason within 60 days of the screening visit

          2. History of hypothalamic amenorrhea or lipodystrophy.

          3. Change in body weight of more than 5% over the past 3 months prior to screening.

          4. Previous history of bariatric procedures for obesity (eg, sleeve gastrectomy, gastric
             bypass, banding, etc).

          5. Procedures for weight reduction (eg, liposuction) or body contouring in the past 6
             months.

          6. Treatment with medications for (over-the-counter [OTC] or prescribed) weight loss (eg,
             lorcaserin, phentermine/topiramate, naltrexone HCl/bupropion HCl, liraglutide) in the
             past 3 months.

          7. History of major psychiatric disorders, eating disorders (eg, bulimia, anorexia).

          8. Current cigarette smoker or former smoker (cigarettes or e-cigarettes) who stopped
             smoking within 3 months prior to screening.

          9. History of recreational drug (including marijuana) or alcohol abuse (&gt;2 drinks per
             day) within a year prior to the screening visit.

         10. Presence of hepatitis B surface antigen (HbsAg) at screening or within 3 months prior
             to dosing.

         11. History of HIV infection or HIV seropositivity at the screening visit.

         12. History of hepatitis C infection or positive hepatitis C antibody test result at
             screening.

         13. Pregnant or breastfeeding women.

        Note: Other inclusion/ exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trial Administrator</last_name>
    <phone>844-734-6643</phone>
    <email>clinicaltrials@regeneron.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2018</study_first_submitted>
  <study_first_submitted_qc>May 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2018</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

